antibody

Rabbit anti LRP5 (pT1492)

MBS462068

0.1 mg

380 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, ELISA, immunohistochemistry

Antibody

Rabbit anti LRP5 (pT1492)

LRP5 (pT1492)

Rabbit anti LRP5 Phospho-specific antibody; Low-density lipoprotein Receptor-related Protein 5 (LRP5); LR3.

low-density lipoprotein receptor-related protein 5; Low-density lipoprotein receptor-related protein 5; low-density lipoprotein receptor-related protein 5; LRP-5; OTTHUMP00000236183; low density lipoprotein receptor-related protein 7; low density lipoprotein receptor-related protein 5

LRP5

LRP5; LRP5; HBM; LR3; OPS; EVR1; EVR4; LRP7; OPPG; BMND1; OPTA1; VBCH2; LRP7

LRP5_HUMAN

Polyclonal

Rabbit

Human, rat, mouse

1615

This antibody recognizes ~175 kDa of human LRP5 protein. It also reacts with mouse and rat. The other species are not tested.

The rabbit IgG is purified by Site-specific Epitope Affinity Purification.

This affinity purified antibody is supplied in sterile Phosphatebuffered saline (pH7.2) containing antibody stabilizer

100 ug/200 ul

The antibodies are stable for 12 months from date of receipt when stored at -20 degree C to -70 degree C. The antibodies can be stored at 2 degree C to 8 degree C for three month without detectable loss of activity. Avoid repeated freezing-thawing cycles.

ELISA, Western Blot, Immunohistochemistry

Suggested Dilution: . Western Blot: 0.1-1 ug/ml. ELISA: 0.01-0.1 ug/ml. Immunoprecipitation: 2-5 ug/ml. Immunohistochemistry: 2-5 ug/ml

Antigen Preparation: A synthetic peptide corresponding to the epitope KATLY at a phosphorylation threonine1492 in LRP5 protein

Positive Control: LRP5 transfected HEK293

Low-desnsity lipoprotein receptor (LDLR)-related protein 5 (LRP5) is a member of the LDLR family which consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. LRP5 cuases several human diseases including bone mineral density variability1, endosteal hyperostosis, autosomal dominant osteopetrosis type I etc. The V171 mutation in LRP5 causes high bone density by impairing the action of a normal antagonist of the Wnt pathway and thus increasing Wnt signaling. The activity of LRP5 and LRP6 can be inhibited by binding of some members of Dickkopf (DKK) family proteins. Upon stimulation with Wnt, LRP5 and LRP6 are phosphorylated at multiple sites including Thr 1479, Ser 1490 and Thr 1492 by kinases such as GSK-3 and CK1.

Davidson, G. et al. (2005), Nature 438, 867-872

119709832

NP_002326.2

NM_002335.2

O75197

175 kDa

MicroRNAs In Cardiomyocyte Hypertrophy Pathway (198784); N-cadherin Signaling Events Pathway (137919); Wnt Signaling Pathway NetPath (198799); Wnt Signaling Pathway And Pluripotency (198847); Wnt Signaling Network Pathway (137962); Wnt Signaling Pathway (83061); Wnt Signaling Pathway (471)

This gene encodes a transmembrane low-density lipoprotein receptor that binds and internalizes ligands in the process of receptor-mediated endocytosis. This protein also acts as a co-receptor with Frizzled protein family members for transducing signals by Wnt proteins and was originally cloned on the basis of its association with type 1 diabetes mellitus in humans. This protein plays a key role in skeletal homeostasis and many bone density related diseases are caused by mutations in this gene. Mutations in this gene also cause familial exudative vitreoretinopathy. [provided by RefSeq]

Function: Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Appears be required for postnatal control of vascular regression in the eye. Required for posterior patterning of the epiblast during gastrulation. Ref.5 Ref.6 Ref.7 Ref.8 Ref.21. Subunit structure: Homodimer; disulfide-linked. Forms phosphorylated oligomer aggregates on Wnt-signaling. By similarity. Component of a Wnt-signaling complex that contains a WNT protein, a FZD protein and LRP5 or LRP6. Interacts with FZD8; the interaction is formed on WNT-binding and signaling. Interacts (via the phosphorylated PPPSP motif domains) with AXIN1; the interaction prevents inhibition of beta-catenin phosphorylation and signaling and is enhanced in the presence of GSK3B and WNT1 or WNT3A. Interacts (via beta-propeller regions 3 and 4) with DKK1; the interaction, enhanced by MESD and/or KREMEN, inhibits beta-catenin signaling by preventing GSK3-mediated phosphorylation of the PPPSP motifs and subsequent, AXIN1 binding. Interacts with MESD; the interaction prevents the formation of LRP5 aggregates, targets LRP5 to the plasma membrane and, when complexed with KREMEN2, increases DKK1 binding. Interacts with CSNK1E. Interacts with SOST; the interaction antagonizes canonical Wnt signaling. Interacts with APCDD1. Ref.5 Ref.6 Ref.7 Ref.8 Ref.9 Ref.10 Ref.11 Ref.12 Ref.13. Subcellular location: Membrane; Single-pass type I membrane protein. Endoplasmic reticulum. By similarity. Note: Chaperoned to the plasma membrane by MESD. Tissue specificity: Widely expressed, with the highest level of expression in the liver. Post-translational modification: Phosphorylation of cytoplasmic PPPSP motifs regulates the signal transduction of the Wnt signaling pathway through acting as a docking site for AXIN1. Polymorphism: Genetic variations in LRP5 define the bone mineral density quantitative trait locus 1 (BMND1) [. MIM:601884]. Variance in bone mineral density influences bone mass and contributes to size determination in the general population. Involvement in disease: Defects in LRP5 are the cause of vitreoretinopathy exudative type 4 (EVR4) [. MIM:601813]. EVR4 is a disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. EVR4 inheritance can be autosomal dominant or recessive. Ref.18 Ref.20 Ref.22 Ref.23 Ref.28 Ref.32 Ref.33Genetic variations in LRP5 are a cause of susceptibility to osteoporosis (OSTEOP) [. MIM:166710]; also known as senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture. Ref.21 Ref.24 Ref.26Defects in LRP5 are the cause of osteoporosis-pseudoglioma syndrome (OPPG) [. MIM:259770]; also known as osteogenesis imperfecta ocular form. OPPG is a recessive disorder characterized by very low bone mass and blindness. Individualy with OPPG are prone to develop bone fractures and deformations and have various eye abnormalities, including phthisis bulbi, retinal detachments, falciform folds or persistent vitreal vasculature. Ref.14 Ref.22 Ref.27 Ref.29 Ref.30Defects in LRP5 are a cause of high bone mass trait (HBM) [. MIM:601884]. HBM is a rare phenotype characterized by exceptionally dense bones. HBM individuals show otherwise a completely normal skeletal structure and no other unusual clinical findings. Ref.15 Ref.16 Ref.25Defects in LRP5 are a cause of endosteal hyperostosis Worth type (WENHY) [. MIM:144750]; also known as autosomal dominant osteosclerosis. WENHY is an autosomal dominant sclerosing bone dysplasia clinically characterized by elongation of the mandible, increased gonial angle, flattened forehead, and the presence of a slowly enlarging osseous prominence of the hard palate (torus palatinus). Serum calcium, phosphorus and alkaline phosphatase levels are normal. Radiologically, it is characterized by early thickening of the endosteum of long bones, the skull and of the mandible. With advancing age, the trabeculae of the metaphysis become thickened. WENHY becomes clinically and radiologically evident by adolescence, does not cause deformity except in the skull and mandible, and is not associated with bone pain or fracture. Affected patients have normal height, proportion, intelligence and longevity. Ref.17Defects in LRP5 are the cause of osteopetrosis autosomal dominant type 1 (OPTA1) [. MIM:607634]. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTA1 is characterized by generalized osteosclerosis most pronounced in the cranial vault. Patients are often asymptomatic, but some suffer from pain and hearing loss. It appears to be the only type of osteopetrosis not associated with an increased fracture rate. Ref.17Defects in LRP5 are the cause of van Buchem disease type 2 (VBCH2)[. MIM:607636]. VBCH2 is an autosomal dominant sclerosing bone dysplasia characterized by cranial osteosclerosis, thickened calvaria and cortices of long bones, enlarged mandible and normal serum alkaline phosphatase levels. Ref.17. Sequence similarities: Belongs to the LDLR family.Contains 4 EGF-like domains.Contains 3 LDL-receptor class A domains.Contains 20 LDL-receptor class B repeats.

0.1 mg

380 USD